Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients
Dupixent® Recommended for EU Approval to Treat Chronic Spontaneous Urticaria in Young Children with Ongoing Symptoms Despite Treatment
Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders
Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva
Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy
EYLEA HD® Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases
Nation's Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search
Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026
Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency
Dupixent® Approved as the First Targeted Medicine in the European Union in Over a Decade for Chronic Spontaneous Urticaria
EYLEA HD® Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion and for Monthly Dosing Across Approved Indications
Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet
EnerCom Announces Initial List of Presenting Companies for the 31st Annual Energy Investment Conference to be held August 17-19, 2026, in Denver, Colorado
